Recently, the validity of this risk assessment algorithm and its abbreviated version, including only three parameters (WHO FC, 6MWD, and BNP/NT-proBNP), have been also tested in CTEPH patients in three studies from large European registries [14,15,16]. This evidence concerns the gene NPPB and chronic thromboembolic pulmonary hypertension.